Design Therapeutics (NASDAQ:DSGN – Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Design Therapeutics to post earnings of ($0.27) per share for the quarter.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. On average, analysts expect Design Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Design Therapeutics Stock Performance
DSGN opened at $4.70 on Monday. The company has a market cap of $266.79 million, a PE ratio of -5.53 and a beta of 1.77. The stock has a 50-day moving average of $4.76 and a 200-day moving average of $5.36. Design Therapeutics has a 52-week low of $2.45 and a 52-week high of $7.77.
Design Therapeutics Company Profile
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
See Also
- Five stocks we like better than Design Therapeutics
- Pros And Cons Of Monthly Dividend Stocks
- How to Build the Ultimate Everything ETF Portfolio
- 3 Warren Buffett Stocks to Buy Now
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
